Cystic Fibrosis Foundation Therapeutics (CFFT), an affiliate of the CF Foundation, has provided $1.7m research award to US-based Savara Pharmaceuticals for advancing the development of AeroVanc (vancomycin hydrochloride inhalation powder). ...
CardioFocus, developer of the HeartLight endoscopic ablation system (EAS) for the treatment of atrial fibrillation (AF), has concluded enrollment of its US pivotal trial evaluating the HeartLight system, for the treatment of symptomatic ...
Covidien, a provider of healthcare products, has introduced the Capnostream 20p bedside monitor, which offers enhanced features for increasing patient safety in hospitals. The Capnostream 20p bedside monitor incorporates Covidien's ...
Tags: Covidien, healthcare products
Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained the US Food and Drug Administration (FDA) approval for its Adempas (riociguat) tablets. Adempas tablets are developed for the treatment of adults with ...
Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained two separate orphan drug designations from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its investigational, oral medication ...
Tags: Drug Designations, Medicine
GlaxoSmithKline and biopharmaceutical company Theravance have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for fluticasone furoate/vilanterol ...
US-based Crosstrees Medical has obtained 510(k) approval from the US Food and Drug Administration (FDA) for the Crosstrees PVA pod system for percutaneous vertebral augmentation (PVA). The FDA approval for the CE marked Crosstrees PVA pod ...
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US Food and Drug Administration (FDA) has recommended the approval of GlaxoSmithKline (GSK) and Theravance's umeclidinium/vilanterol as a treatment for chronic obstructive ...
Tags: Health, Medicine, Investigational Copd Drug
One of the world's top-selling drugs—GlaxoSmithKline PLC's $8-billion-a-year asthma treatment Advair—became more vulnerable to generic competition after the U.S. Food and Drug Administration issued guidance on the regulatory ...
Biopharmaceutical firm Cubist Pharmaceuticals is voluntarily recalling four lots of Cubicin (daptomycin for injection) 500mg in 50ml single use vials in the US primarily due to presence of glass particulates. The company said that no ...
Tags: Cubicin Injection, Cubist
The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee has recommended approval of Bayer’s oral soluble guanylate cyclase (sGC) stimulator, riociguat, in two forms of pulmonary ...
Tags: FDA Advisory Committee
Adamis Pharmaceuticals has signed an agreement to completely acquire 3M Company's MMM -0.36% Taper Dry Powder Inhaler (DPI) technology. Additionally, the company has entered into an agreement to exclusively license the platform technology ...
Tags: Adamis Pharmaceuticals, Dry Powder
Swiss drugmaker Novartis has announced that once-daily dual bronchodilator, Ultibro Breezhaler (QVA149), has achieved positive CHMP opinion for the treatment of chronic obstructive pulmonary disease (COPD). Ultibro Breezhaler was ...
GlaxoSmithKline (GSK) and Theravance have withdrawn license application for the use of inhaled drug fluticasone furoate (FF) and vilanterol (VI), with proposed brand name of Relvar Ellipta, as treatment for chronic obstructive pulmonary ...
Tags: Japan, GSK, Relvar License
Sanovas, a US-based micro invasive surgical solutions developer, has entered into a patent license and joint development agreement with Mayo Clinic, to commercialise technologies in bronchial smooth muscle modification. The agreement aims ...